Harold V. Barron
Independent DirectorDr. Harold V. Barron, M.D. F.A.C.C., also known as Hal, is Founder of Altos Labs, Inc. and serves as its Director and serves as its Chief Executive Officer and Co-Chairman of the Board since 2022. He is Independent Director of Quantinuum Inc. from June 4, 2026. He served as Chief Scientific Officer and President of Research & Development at GSK plc since April 1, 2018 until August 1, 2022 and had been its Director since January 1, 2018 and serves as its Non-Executive Director since August 1, 2022. He served as Member of Scientific Advisory Board of Verily Life Sciences LLC until October 2021. Prior to GSK, he served as the President of Research and Development at Calico LLC (California Life Company), a subsidiary of Alphabet Inc. from November 2013 to December 2017. Dr. Barron has been employed at Calico Life Sciences LLC since November 2013. He served as the Chief Medical Officer and Head of Global Product Development at Hoffmann-La Roche Ltd. from January 2010 to November 2013 and Roche Molecular Systems Inc. He served as an Executive Vice President of Global Development at Genentech, Inc. and served as its Chief Medical Officer from March 2004 to November 2013. He served as the Chief Medical Officer of Roche Holding AG. He was an Executive Vice President, Head of Global Product Development and Chief Medical Officer of Roche Pharmaceuticals. His academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics and Associate Clinical Professor of Medicine/Cardiology. He joined Genentech Inc. in 1996 as a Clinical Scientist. Dr. Barron served as Executive Vice President of Genentech from June 2009 to November 2013. He served as a Senior Vice President of Development of Genentech, Inc. from June 2004 to June 2010. He served positions as Head of Development, Associate Director and Director of Cardiovascular Research and Senior Director of the Biotherapeutics group within Medical Affairs. From May 2002 to June 2004, he served as Vice President of Medical Affairs and led the newly formed Development organization that is being created by combining Genentech's Medical Affairs and Development Sciences departments. He served as Director of GRAIL, Inc. since August 2018. He is globally recognized for his clinical and scientific leadership. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals. He was a Director of Juno Therapeutics Inc. since September 2014 until March 6, 2018 acquisition by Celgene Corporation. He served as a Director of Arête Therapeutics, Inc. He served as a Director of Alexza Pharmaceuticals Inc. from December 2007 to May 21, 2013. Dr. Barron has Medical Degree from Yale University in 1989 and Bachelor of Science in Engineering Physics from Washington University of St. Louis in 1985.
Positions
- Company NameQuantinuum Inc.Stock CodeQNTPositionIndependent DirectorColleagues
- RHRajeeb HazraPresident, CEO & Director
- KDKenneth D. DenmanIndependent Chairman
- NSNitesh SharanChief Financial Officer
- RJRobin J. SchulmanChief Legal Officer & Company Secretary
- LSLawrence S. SchwartzChief Marketing Officer
- RGRory G. O’ByrneChief People Officer
- EBEric BranderizIndependent Director
- JJJoseph JimenezIndependent Director
